Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?

AUTOR(ES)

Fanos, Vassilios, Pusceddu, Michele, Dessì, Angelica, Marcialis, Maria Antonietta

FONTE

Clinics

DATA DE PUBLICAÇÃO

2011

RESUMO

Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.

Documentos Relacionados

• Conservative treatment for patent ductus arteriosus in the preterm
• Diagnosis of patent ductus arteriosus in the preterm newborn.
• Left ventricular preload reserve in preterm infants with patent ductus arteriosus
• Extrapleural Closure of Patent Ductus Arteriosus: How We Do It
• A NEW ANGIOCARDIOGRAPHIC SIGN OF PATENT DUCTUS ARTERIOSUS